| Identification | Back Directory | [Name]
2'-DEOXY-L-CYTIDINE | [CAS]
40093-94-5 | [Synonyms]
Torcitabine
L-2'-deoxycytidine
2'-DEOXY-L-CYTIDINE
BETA-L-2'-DEOXYCYTIDINE
2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-b-L-erythro-pentofuranosyl)-
2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-β-L-erythro-pentofuranosyl)-
4-amino-1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one
4-AMino-1-((2R,4R,5S)-4-hydroxy-5-(hydroxyMethyl)tetrahydrofuran-2-yl)pyriMidin-2(1H)-one | [EINECS(EC#)]
500-100-4 | [Molecular Formula]
C9H13N3O4 | [MDL Number]
MFCD02683609 | [MOL File]
40093-94-5.mol | [Molecular Weight]
227.22 |
| Chemical Properties | Back Directory | [Boiling point ]
497.6±55.0 °C(Predicted) | [density ]
1.73±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 250 mg/mL (1100.26 mM) | [pka]
14.03±0.60(Predicted) | [Water Solubility ]
Water: 250 mg/mL (1100.26 mM) |
| Hazard Information | Back Directory | [Description]
Torcitabine (b-L-2u-deoxycytidine) (L-dC) is the b-L-enantiomer of the natural nucleoside D-cytidine. The drug is currently under development by Idenix as an antiviral agent for the treatment of chronic hepatitis B virus infection. Torcitabine has poor oral bioavailability, but its 3u,5u-divaline ester (val-L-dC) and the 3u-monovaline ester, valtorcitabine dihydrochloride, have excellent oral bioavailability and consequently the torcitabine prodrug, valtorcitabine, has replaced torcitabine in clinical development. | [Uses]
Torcitabine and its prodrug, valtorcitabine, are investigational drugs being developed solely for the treatment of chronic HBV infection. Torcitabine itself has undergone preliminary phase I/II clinical trials in HBeAg-positive patients, initially as the 3u,5u-divalyl prodrug in escalating doses of 50, 100, 200, and 400 mg/day, but later as the more stable monovaline ester form, valtorcitabine dihydrochloride, and administered to four cohorts in doses of 300, 600, 900, and 1200 mg/ day for 28 days. | [storage]
Store at -20°C |
|
|